Deadlock Tweet and Microcap.com update
Early Thursday morning Danny Deadlock posted an Alert on TLT to his followers at
www.twitter.com/tsxalerts . He posted a couple more tweets by late in the day but also emailed an alert to his subscribers at
www.microcap.com shortly after the theralase news went out.
This evening he sent out an update to us microcap subscribers with a VERY bullish tone. He references a stock he followed in 2009 and 2010 called YM Biosciences. That stock went from a $26 million market cap to a buyout by Gilead in December 2010 for $500 million.
I don't believe YM had any revenue but a couple drug candidates in the pipeline undergoing late stage drug trials. Gilead wanted one specific to a bone marrow disorder but they also got a good one related to a blood cancer.
The point he was trying to make was that Gilead after YM's cash position was paying $400 Million for that drug POTENTIAL as the main drug Gilead wanted did not yet have fda approval.
Even after this TLT run to 40 cents, the market values the company at $30 Million. Deadlock makes the point that if Gilead was prepared to pay 400 million for what they did, what could a large pharmaceutical company value TLT at "if" this drug and technology are validated in humans.
He is VERY careful to point out the early stage in mice and that all this will take money and time. But I think shareholders here need to be thinking longer term and that pennies here or there could be irrelevant down the road.
The gains and volume thursday may be the tip of the icerberg when considering future value and potential. It will not come overnight but i am not taking the chance of NOT owning a piece of this. IF history is to be made here, I want to own a small piece of it.